Leap Therapeutics Inc (LPTX) - Total Liabilities
Based on the latest financial reports, Leap Therapeutics Inc (LPTX) has total liabilities worth $8.70 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Leap Therapeutics Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Leap Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Leap Therapeutics Inc (LPTX) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Leap Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Leap Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gabelli Global Utility & Income Tr
NYSE MKT:GLU
|
USA | $291.78K |
|
Supercomnet Technologies Bhd
KLSE:0001
|
Malaysia | RM21.42 Million |
|
OBI Pharma
TWO:4174
|
Taiwan | NT$748.70 Million |
|
INNATE PHARMA SP.ADR/1
F:IDDA
|
Germany | €84.42 Million |
|
Norsk Titanium AS
OL:NTI
|
Norway | Nkr14.08 Million |
|
Energoaqua a.s.
PR:ENRGA
|
Czech Republic | Kč791.48 Million |
|
Jaya Agra Wattie Tbk
JK:JAWA
|
Indonesia | Rp2.56 Trillion |
|
CAPRAL LTD.
F:CBZ
|
Germany | €239.10 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Leap Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Leap Therapeutics Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Leap Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Leap Therapeutics Inc (2012–2024)
The table below shows the annual total liabilities of Leap Therapeutics Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $14.08 Million | +10.97% |
| 2023-12-31 | $12.68 Million | +267.76% |
| 2022-12-31 | $3.45 Million | -65.59% |
| 2021-12-31 | $10.02 Million | +233.02% |
| 2020-12-31 | $3.01 Million | -67.27% |
| 2019-12-31 | $9.20 Million | -7.09% |
| 2018-12-31 | $9.90 Million | -44.84% |
| 2017-12-31 | $17.95 Million | +177.92% |
| 2016-12-31 | $6.46 Million | +404.85% |
| 2015-12-31 | $1.28 Million | -48.59% |
| 2014-12-31 | $2.49 Million | +26.23% |
| 2013-12-31 | $1.97 Million | -57.27% |
| 2012-12-31 | $4.61 Million | -- |
About Leap Therapeutics Inc
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-… Read more